Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Veliparib improves PFS in high-grade serous epithelial ovarian cancer

Publish date:: October 17, 2019

Key clinical point: Adding veliparib to frontline chemotherapy and maintenance for high-grade serous epithelial ovarian cancer significantly extended progression-free survival.

Major finding: Median progression-free survival was 23.5 in the veliparib group versus 17.3 months in the control group.

Study details: The randomized, phase 3 VELIA/GOG-3005 trial of 1,140 patients.

Disclosures: The study was sponsored by AbbVie. Dr. Coleman and Dr. Oaknin reported relationships with numerous pharmaceutical companies.

Citation:

Coleman RL et al. ESMO 2019, Abstract LBA3-PR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,